Biodexa Pharmaceuticals
BDRX
3 hedge funds and large institutions have $29.3K invested in Biodexa Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.89% less ownership
Funds ownership: 2.13% → 1.25% (-0.89%)
40% less funds holding
Funds holding: 5 → 3 (-2)
66% less capital invested
Capital invested by funds: $87.3K → $29.3K (-$58K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$16.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$9.19K |
| 3 |
Morgan Stanley
New York
|
-$4.04K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$522 |
| 5 |
GI
GAMMA Investing
Foster City,
California
|
-$81 |
BDRX Hedge Fund Activity: Q4 2024 in Review
3 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q4 2024, worth a combined $29.3K — down 66% from $87.3K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BDRX and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was UBS Group, cutting an estimated $16.5K.
- 3 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q4 2024, down from 5 in Q3 2024.
- Funds reported $29.3K of Biodexa Pharmaceuticals stock for Q4 2024, down 66% quarter-over-quarter.
- 0 funds opened new Biodexa Pharmaceuticals positions in Q4 2024 and 2 closed out, a net change of -2 holders.
- The largest Biodexa Pharmaceuticals seller in Q4 2024 was UBS Group, an estimated $16.5K sold.
Based on aggregated 13F filings for Q4 2024.